Atia Vision is a technology company.
Atia Vision has raised $3.0M across 1 funding round.
Atia Vision has raised $3.0M in total across 1 funding round.
Atia Vision has raised $3.0M in total across 1 funding round.
Atia Vision's investors include Artis Ventures (AV).
Atia Vision, Inc. is a medical device company developing the OmniVu™ Lens System, a next-generation dual-optic, modular shape-changing intraocular lens (IOL) for presbyopia correction in cataract patients.[1][2][3][4] The product targets patients undergoing cataract surgery, addressing the limitations of current presbyopia-correcting lenses by restoring the full dynamic range of functional vision—seamless transitions from distance to near—while minimizing visual disturbances like halos or glare, leveraging the eye's natural accommodative mechanism.[1][2][4] Backed by Shifamed and a $42M Series E financing in 2022, the company achieved FDA Investigational Device Exemption (IDE) approval in May 2025 to start U.S. feasibility clinical trials, building on global data from over 75 eyes and early presentations at the 2023 ASCRS meeting, signaling strong growth momentum toward commercialization.[1][4]
Founded in 2014, Atia Vision emerged from the Shifamed portfolio, a Silicon Valley-based medical innovation incubator specializing in ophthalmology breakthroughs.[3][4][6] The company's technology originated as a Shifamed project focused on accommodating IOLs to improve outcomes in the massive cataract and presbyopia market, humanizing vision restoration by mimicking natural eye function.[1][3] Early milestones include first-in-human clinical data presented at the 2023 ASCRS meeting, a $42M Series E close in August 2022 led by Cormorant Asset Management to scale clinical programs and manufacturing, and FDA IDE approval in May 2025 under CEO Mariam Maghribi, marking a pivot to U.S. trials after promising international results.[1][4]
Atia Vision rides the wave of advancing IOL innovations amid rising global cataract surgeries—over 28 million annually—driven by aging populations and demand for presbyopia solutions that match natural vision.[3] Timing aligns with FDA's push for next-gen devices post-IDE approval, capitalizing on market forces like post-pandemic elective procedure rebounds and medtech investments in minimally invasive ophthalmology.[1][4] As a Shifamed spinout, it influences the ecosystem by challenging incumbents like Alcon and Johnson & Johnson Vision, potentially elevating standards for dynamic-accommodation tech and expanding Shifamed's ophthalmology footprint.[3][6]
Atia Vision is poised for pivotal U.S. clinical readouts from its FDA-approved feasibility study, potentially fast-tracking PMA submission and market entry by 2027-2028 if data mirrors global successes.[1][4] Trends like AI-optimized lens customization and value-based care will shape its path, amplifying influence as the go-to for disturbance-free presbyopia correction in cataracts. Expect partnerships or acquisition interest from big vision players, solidifying its role in redefining post-surgical vision—truly insightful, as promised.[1][2]
Atia Vision has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Series B in May 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2015 | $3.0M Series B | Artis Ventures (AV) |